TP53 and gastric adenocarcinoma: For example, EA with CCNE1 gain demonstrated intermediate frequency of TP53, CDKN2A, ARIDA, and ERBB2 alterations relative to CCNE1 neutral and amplified tumors, while gastric adenocarcinoma with CCNE1 gain showed intermediate levels of TP53 mutation, CDH1 mutation, KMT2D mutation, LOH, and ERBB2 amplification.